Barclays PLC Macrogenics Inc Transaction History

Barclays PLC

$436 Billion
Q2 2025

A detailed history of Barclays PLC transactions in Macrogenics Inc stock. As of the latest transaction made, Barclays PLC holds 57,818 shares of MGNX stock, worth $112,166. This represents 0.0% of its overall portfolio holdings.

Number of Shares

57,818

Previous 57,818 -0.0%

Holding current value

$112,166

Previous $70,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$1.06 - $1.79 $55,458 - $93,651	-52,319 Reduced 47.5%	57,818 $70,000
Q1 2025 May 15, 2025	SELL	$1.26 - $3.49 $2,210 - $6,121	-1,754 Reduced 1.57%	110,137 $140,000
Q4 2024 Feb 13, 2025	BUY	$3.18 - $4.46 $41,778 - $58,595	13,138 Added 13.3%	111,891 $363,000
Q3 2024 Nov 15, 2024	BUY	$3.0 - $5.55 $160,917 - $297,696	53,639 Added 118.9%	98,753 $325,000
Q2 2024 Aug 14, 2024	SELL	$3.31 - $18.51 $121,238 - $677,984	-36,628 Reduced 44.81%	45,114 $191,000
Q1 2024 May 15, 2024	SELL	$9.77 - $21.47 $740,458 - $1.63 Million	-75,789 Reduced 48.11%	81,742 $1.2 Million
Q4 2023 Feb 15, 2024	BUY	$4.48 - $10.11 $104,195 - $235,138	23,258 Added 17.32%	157,531 $1.52 Million
Q3 2023 Nov 07, 2023	BUY	$4.48 - $6.19 $79,443 - $109,767	17,733 Added 15.22%	134,273 $624,000
Q2 2023 Aug 03, 2023	SELL	$4.62 - $7.54 $109,068 - $178,004	-23,608 Reduced 16.85%	116,540 $622,000
Q1 2023 May 04, 2023	BUY	$4.82 - $7.24 $44,474 - $66,803	9,227 Added 7.05%	140,148 $1.01 Million
Q4 2022 Feb 13, 2023	BUY	$3.34 - $6.98 $233,352 - $487,664	69,866 Added 114.43%	130,921 $877,000
Q3 2022 Nov 03, 2022	SELL	$3.01 - $5.22 $8,713 - $15,111	-2,895 Reduced 4.53%	61,055 $211,000
Q2 2022 Aug 12, 2022	BUY	$2.25 - $9.99 $56,009 - $248,681	24,893 Added 63.74%	63,950 $189,000
Q1 2022 May 16, 2022	SELL	$8.12 - $16.9 $297,671 - $619,537	-36,659 Reduced 48.42%	39,057 $344,000
Q4 2021 Feb 14, 2022	BUY	$15.91 - $21.88 $138,146 - $189,984	8,683 Added 12.95%	75,716 $1.22 Million
Q3 2021 Nov 09, 2021	SELL	$19.74 - $28.7 $95,146 - $138,334	-4,820 Reduced 6.71%	67,033 $1.4 Million
Q2 2021 Aug 13, 2021	SELL	$20.49 - $35.63 $717,190 - $1.25 Million	-35,002 Reduced 32.76%	71,853 $1.93 Million
Q1 2021 May 13, 2021	BUY	$18.99 - $33.2 $1.65 Million - $2.88 Million	86,844 Added 433.98%	106,855 $3.4 Million
Q4 2020 Feb 11, 2021	SELL	$19.41 - $26.0 $128,707 - $172,406	-6,631 Reduced 24.89%	20,011 $458,000
Q3 2020 Nov 12, 2020	SELL	$24.69 - $31.6 $1.64 Million - $2.1 Million	-66,612 Reduced 71.43%	26,642 $672,000
Q2 2020 Aug 12, 2020	BUY	$5.2 - $29.12 $396,396 - $2.22 Million	76,230 Added 447.78%	93,254 $2.6 Million
Q1 2020 May 13, 2020	SELL	$4.28 - $12.11 $136,429 - $386,018	-31,876 Reduced 65.19%	17,024 $98,000
Q4 2019 Feb 10, 2020	BUY	$7.95 - $12.27 $151,312 - $233,534	19,033 Added 63.73%	48,900 $531,000
Q3 2019 Nov 14, 2019	SELL	$12.44 - $17.48 $36,125 - $50,761	-2,904 Reduced 8.86%	29,867 $381,000
Q2 2019 Aug 14, 2019	BUY	$14.51 - $19.71 $208,102 - $282,680	14,342 Added 77.82%	32,771 $556,000
Q1 2019 May 15, 2019	BUY	$11.11 - $25.6 $204,746 - $471,782	18,429 New	18,429 $331,000
Q4 2018 Feb 14, 2019	SELL	$11.75 - $21.42 $193,957 - $353,579	-16,507 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$19.26 - $23.46 $262,648 - $319,924	13,637 Added 475.16%	16,507 $354,000
Q2 2018 Aug 14, 2018	SELL	$19.78 - $24.67 $241,948 - $301,763	-12,232 Reduced 81.0%	2,870 $59,000
Q1 2018 May 15, 2018	BUY	$18.89 - $32.46 $128,829 - $221,377	6,820 Added 82.35%	15,102 $380,000
Q4 2017 Feb 14, 2018	BUY	$16.19 - $20.3 $117,426 - $147,235	7,253 Added 704.86%	8,282 $157,000
Q3 2017 Nov 14, 2017	BUY	$15.52 - $18.94 $15,970 - $19,489	1,029	1,029 $20,000

Others Institutions Holding MGNX

# of Institutions

117

Shares Held

52.3M

Call Options Held

55.3K

Put Options Held

35.9K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $119M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account